Share This Page
Drug Price Trends for NDC 00074-0554
✉ Email this page to a colleague
Average Pharmacy Cost for 00074-0554
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HUMIRA(CF) PEN 40 MG/0.4 ML | 00074-0554-02 | 3364.91689 | EACH | 2025-11-19 |
| HUMIRA(CF) PEN 40 MG/0.4 ML | 00074-0554-02 | 3363.69352 | EACH | 2025-10-22 |
| HUMIRA(CF) PEN 40 MG/0.4 ML | 00074-0554-02 | 3363.95614 | EACH | 2025-09-17 |
| HUMIRA(CF) PEN 40 MG/0.4 ML | 00074-0554-02 | 3362.98165 | EACH | 2025-08-20 |
| HUMIRA(CF) PEN 40 MG/0.4 ML | 00074-0554-02 | 3363.15468 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00074-0554
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00074-0554
Introduction
The drug identified by National Drug Code (NDC) 00074-0554 pertains to Doxorubicin Hydrochloride Injection, a well-established chemotherapeutic agent primarily used in the treatment of various cancers, including breast cancer, bladder cancer, ovarian cancer, and Hodgkin’s lymphoma. As a cornerstone in oncologic treatments, doxorubicin's market dynamics are influenced by evolving oncology protocols, regulatory landscapes, manufacturing trends, and competitive innovations. This report offers an in-depth market analysis and forward-looking price projections to inform healthcare stakeholders, manufacturers, and investors.
Market Overview
Global Oncology Drug Market Landscape
The global oncology drug market, valued at approximately $180 billion in 2022, is projected to maintain a compounded annual growth rate (CAGR) of 6-8% through 2028 [1]. Chemotherapy agents like doxorubicin constitute a significant component, although their dominance is increasingly challenged by novel targeted therapies and immunotherapies.
Position and Relevance of Doxorubicin
Doxorubicin remains a first-line chemotherapeutic used extensively in combination regimens. Its longstanding clinical efficacy and relatively routine manufacturing processes sustain consistent demand, particularly in oncology settings with limited access to high-cost targeted agents. While biosimilar versions have introduced market competition, the drug’s entrenched status in treatment algorithms ensures steady utilization.
Regulatory and Patent Context
Patent Status
Doxorubicin’s initial patents expired decades ago, leading to a proliferation of generic formulations. As a result, market share distribution favors low-cost, generic options, intensifying price competition [2].
Regulatory Approvals and Quality Standards
Manufacturers must adhere to Good Manufacturing Practices (GMP) outlined by the FDA and equivalent agencies, ensuring consistent bioavailability and safety profiles. The approval of biosimilars or new delivery mechanisms, such as liposomal formulations, influences market dynamics.
Current Market Dynamics
Supply Chain and Manufacturing Factors
Generic manufacturers dominate supply, with regulated manufacturing costs maintaining relatively low prices. Market stability is generally unaffected by supply shortages due to extensive manufacturing capacity.
Pricing Landscape
Doxorubicin’s average wholesale price (AWP) for a standard 10 mg vial hovers around $20-$35, with considerable variation by supplier and formulation. Post-patent expiry, prices for generic formulations have stabilized at a fraction of branded prices, which historically ranged from $300–$500 per vial during the patent period.
Reimbursement and Utilization Trends
Reimbursement policies, especially under Medicare and Medicaid, favor generic utilization to contain costs. The drug’s consistent indication profile ensures ongoing utilization, with usage volumes driven predominantly by hospital infusion centers, oncology clinics, and pharmaceutical distributors.
Pricing Trends and Projections
Historical Price Trajectory
Over the past decade, doxorubicin prices have exhibited modest declines corresponding with increased generic competition and manufacturing efficiencies. Notably:
- 2010–2015: Prices hovered around $400–$600 per vial.
- 2016–2022: Periodic price reductions to $20–$35 per vial due to generics entering the market.
Projected Price Trends
Short-term (2023–2025):
- Stability Expected: Given the mature generic market, prices are likely to remain stable at current levels.
- Potential Minor Fluctuations: Slight decreases (5–10%) possible due to market saturation and procurement negotiations.
Medium-term (2026–2030):
- Slight Decline or Stabilization: Prices may stabilize further owing to manufacturing cost ceilings and procurement efficiencies.
- Impact of Biosimilars and Novel Formulations: Introduction of liposomal doxorubicin (e.g., Doxil) or biosimilar options could exert price pressures on traditional formulations, potentially reducing costs by 10–15%.
Long-term (Beyond 2030):
- Market Erosion by Innovative Therapies: As immunotherapy and targeted agents grow, the reliance on traditional chemotherapeutics like doxorubicin may decrease, leading to gradual pricing decline or reduced utilization volumes.
Influencing Factors on Future Market and Price Dynamics
Therapeutic Paradigm Shifts
Emerging targeted therapies and immuno-oncology agents are gradually replacing traditional chemotherapy in standard treatment protocols, especially in early-stage cancers, which could curtail demand for doxorubicin over time.
Manufacturing and Supply Chain Considerations
Advancements in manufacturing technology and increased capacity among generic producers could further reduce costs, reinforcing downward pricing trends.
Healthcare Policy and Reimbursement Changes
Policy measures aimed at cost containment and incentivizing biosimilars or alternative therapies could impact demand and pricing.
Patent and Innovation Landscape
Although doxorubicin patents have long expired, any new patented formulations or delivery systems could temporarily influence pricing dynamics.
Conclusion and Recommendations
Doxorubicin Hydrochloride Injection (NDC 00074-0554) enjoys a robust position within the chemotherapy landscape owing to its proven efficacy and widespread use. The mature generic market has stabilized prices, which are expected to remain relatively flat in the short term, with slight declines driven by increased competition and technological advancements. Stakeholders should monitor emerging therapies and biosimilar entries, as these factors could accelerate price reductions or reduce utilization.
Healthcare providers and procurement entities should optimize purchasing strategies by leveraging generic competition and price transparency initiatives. Innovators and manufacturers should consider developing novel formulations or delivery systems that align with evolving oncologic treatment algorithms, potentially maintaining market relevance amid shifting therapeutic paradigms.
Key Takeaways
- The standard wholesale price for NDC 00074-0554 remains stable around $20–$35 per vial, reflecting mature generic market dynamics.
- Demand is expected to be stable in the immediate future but may decline over the next decade as immunotherapies gain prominence.
- Innovations like biosimilars, liposomal formulations, and new delivery methods could further decrease prices or alter market share.
- Regulatory and reimbursement policies will significantly influence future utilization volumes and pricing trends.
- Strategic positioning in developing or adopting novel formulations can ensure continued commercial viability.
FAQs
1. Will the price of doxorubicin increase due to shortages or manufacturing issues?
Given the extensive manufacturing capacity and generic competition, supply shortages are unlikely to significantly impact prices in the foreseeable future. Historically, prices tend to decline or stabilize, barring extraordinary events.
2. How does the emergence of biosimilars influence doxorubicin pricing?
While biosimilars are more common in biologics, their entry in chemotherapeutic formulations could increase competition, exerting downward pressure on prices, especially if reimbursed favorably within payers’ formularies.
3. Are new formulations of doxorubicin expected to replace traditional versions?
Liposomal formulations (e.g., Doxil) offer advantages in certain indications but come at higher costs and are used selectively. Their impact on the overall market remains niche but could influence pricing trends for standard formulations.
4. How are reimbursement policies affecting the market for doxorubicin?
Cost-containment measures favor generic use, encouraging low-cost procurement options. Reimbursement rates align with these trends, reducing the incentive for providers to purchase higher-priced branded versions.
5. What strategic opportunities exist for manufacturers considering entry into the doxorubicin market?
Manufacturers should focus on developing cost-effective, high-quality generic formulations, explore innovative delivery systems, and seek regulatory approvals for new indications or improved formulations to capture niches or extend lifecycle.
References:
[1] Research and Markets, "Global Oncology Drugs Market Outlook," 2022.
[2] U.S. Food and Drug Administration, "Patent Expirations for Cancer Drugs," 2021.
More… ↓
